If the FDA doesn't release its overdue guidance on social media soon, biopharma may beat it to the door with industry best practices for communicating directly with patients in interactive neighborhoods like Facebook.
WASHINGTON – Yes, Medicare Part D has produced larger than expected savings, but it might save even more if rebates on brand drugs and biologics were statutory, according to the Health and Human Services Office of Inspector General (OIG).
Intercept Pharmaceuticals Inc. is looking to a $163 million collaboration agreement with Les Laboratoires Servier to help it scale the mountainous challenges involved in developing a novel diabetes drug.
All those warnings about price pressures and reimbursement woes – they didn’t come from Chicken Little. The sky really could be falling for drugmakers that insist on pricing their products based on what the market used to bear. Rather than making the same old arguments about the cost of drug development, biopharma needs to understand that today’s market simply can’t bear the prices of yesterday’s bestsellers. Yes, a lot of factors are involved in drug pricing, and a lot of middle men add to the costs here in the U.S. But when it comes finger-pointing time, drugmakers tend to be...
WASHINGTON – Fears that the FDA and National Institutes of Health (NIH) may loosen researchers' collars on conflicts of interest have government watchdogs nipping at their heels.
